The First Weekly Updated Model Allows Pharma Companies to Dynamically Plan for the Spread of COVID-19 Using Flexible Forecasting Tools for Scenario Planning and Decision Support
Trinity Life Sciences, a leader in global life sciences solutions, introduces the first weekly-updated, forecasting model for drugs and treatments impacted by COVID-19. Trinity COVIDCast is a flexible SEIR (susceptible, exposed, infectious, recovered) model that forecasts COVID-19 case counts and hospitalizations across the United States, EU5, China and Japan. COVIDCast is designed for forecasting or brand planning teams working on COVID-specific drugs, diagnostics and vaccines as well as for teams who are working to forecast the impact on non-COVID drugs due to the virus.
Trinity COVIDCast is designed to be flexible in the face of emerging scientific literature, adaptive to the most recent case data and pliable to emerging consensus from public health experts on plausible real-world scenarios. The models can be configured for any new or existing forecast using a combination of Excel and web-enabled toolsets. Weekly updates are compatible with TrinityEDGE, Trinity’s proprietary technology platform for data, analytics and reporting.
Recommended AI News: Cloud Elements Partners With SugarCRM To Launch New Integration Solution In 90 Days
“Life sciences leaders must stay up-to-date on the latest developments related to the spread and impact of COVID-19,” said Dave Fitzhenry, CEO, Trinity. “With several hundred COVID-19 drugs in testing or with known clinical aspirations, several thousand publications each week, and constantly changing policy dynamics related to COVID-19 it can be very difficult to stay abreast of the data needed to make critical decisions. The Trinity COVIDCast model is designed specifically for life sciences companies looking to project COVID-19 for comprehensive business planning.”
Recommended AI News: AiThority Interview With Pankaj Chowdhry, CEO And Founder At FortressIQ
COVIDCast includes multiple pre-built scenarios with the ability to plug in proprietary assumptions. The model is highly configurable to apply to any situation or therapy that is affected by the spread of COVID-19 and the resulting cascade of impacts.
Recommended AI News: Blueprint And Blue Prism Partner To Drive RPA At Enterprise Scale
Comments are closed.